schliessen

Filtern

 

Bibliotheken

Endometrial cancer

Summary Endometrial cancer is the most common gynaecological tumour in developed countries, and its incidence is increasing. The most frequently occurring histological subtype is endometrioid adenocarcinoma. Patients are often diagnosed when the disease is still confined to the uterus. Standard trea... Full description

Journal Title: The Lancet (British edition) 2015, Vol.387 (10023), p.1094-1108
Main Author: Morice, Philippe, Dr Prof
Other Authors: Leary, Alexandra, MD , Creutzberg, Carien, Prof , Abu-Rustum, Nadeem, Prof , Darai, Emile, Prof
Format: Electronic Article Electronic Article
Language: English
Subjects:
Quelle: Alma/SFX Local Collection
Publisher: England: Elsevier Ltd
ID: ISSN: 0140-6736
Link: https://www.ncbi.nlm.nih.gov/pubmed/26354523
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_miscellaneous_1777490176
title: Endometrial cancer
format: Article
creator:
  • Morice, Philippe, Dr Prof
  • Leary, Alexandra, MD
  • Creutzberg, Carien, Prof
  • Abu-Rustum, Nadeem, Prof
  • Darai, Emile, Prof
subjects:
  • Abridged Index Medicus
  • Adult
  • Aged
  • Antineoplastic Agents - therapeutic use
  • Cancer
  • Chemotherapy
  • Combined Modality Therapy
  • Comorbidity
  • Early Detection of Cancer
  • Endometrial cancer
  • Endometrial Neoplasms - epidemiology
  • Endometrial Neoplasms - pathology
  • Endometrial Neoplasms - therapy
  • Female
  • Genetic Counseling - methods
  • Humans
  • Hysterectomy
  • Internal Medicine
  • Lymph Node Excision - methods
  • Metastasis
  • Middle Aged
  • Molecular Targeted Therapy - methods
  • Mutation
  • Mutation - genetics
  • Neoadjuvant Therapy
  • Neoplasm Invasiveness
  • Neoplasm Metastasis
  • Neoplasm Recurrence, Local - therapy
  • Neoplasm Staging
  • Preoperative Care - methods
  • Prognosis
  • Risk Factors
  • Survival Analysis
  • Tumors
  • Uterine Hemorrhage - etiology
  • Womens health
ispartof: The Lancet (British edition), 2015, Vol.387 (10023), p.1094-1108
description: Summary Endometrial cancer is the most common gynaecological tumour in developed countries, and its incidence is increasing. The most frequently occurring histological subtype is endometrioid adenocarcinoma. Patients are often diagnosed when the disease is still confined to the uterus. Standard treatment consists of primary hysterectomy and bilateral salpingo-oophorectomy, often using minimally invasive approaches (laparoscopic or robotic). Lymph node surgical strategy is contingent on histological factors (subtype, tumour grade, involvement of lymphovascular space), disease stage (including myometrial invasion), patients' characteristics (age and comorbidities), and national and international guidelines. Adjuvant treatment is tailored according to histology and stage. Various classifications are used to assess the risks of recurrence and to determine optimum postoperative management. 5 year overall survival ranges from 74% to 91% in patients without metastatic disease. Trials are ongoing in patients at high risk of recurrence (including chemotherapy, chemoradiation therapy, and molecular targeted therapies) to assess the modalities that best balance optimisation of survival with the lowest adverse effects on quality of life.
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 0140-6736
fulltext: fulltext
issn:
  • 0140-6736
  • 1474-547X
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.8724155
LOCALfalse
PrimoNMBib
record
control
sourceidgale_proqu
recordidTN_cdi_proquest_miscellaneous_1777490176
sourceformatXML
sourcesystemPC
galeidA463055763
sourcerecordidA463055763
originalsourceidFETCH-LOGICAL-c693t-2e2084113976b281e1882dff0e6fd77d2e854f5767756015b29dd4c434404eaf3
addsrcrecordideNqNkl1rFDEUhoNY7Fq98V4RvKng1JPJ1wyCUkptCwUvVPAuZJMza-p8bJMZof_ezK52p8tiSyCB8Jwnb-Al5CWFIwpUvv8KlEMmFZOHVLwFoAwyeERmlCueCa5-PCazW2SfPI3xCgC4BPGE7OeSCS5yNiMvTlvXNdgHb-rX1rQWwzOyV5k64vO_5wH5_vn028l5dvnl7OLk-DKzsmR9lmMOBaeUlUrO84IiLYrcVRWgrJxSLsdC8EooqZSQQMU8L53jljPOgaOp2AE5XHuXobseMPa68dFiXZsWuyFqqpTiJVAlE_pmC73qhtCmdCPFgDNW0A21MDVq31ZdH4wdpfpY0FIyDoL_l-KSgUiRWaKOdlBpOWy87VqsfLq_o33QwPSFVzsG9NS4E5ga3k2A-RB9izFt0S9-9nFhhhjvJnwAPrWLNW5DF2PASi-Db0y40RT0WEG9qqAe-6Wp0KsKatjEXg7zBt3t1L_OJeDDltj63vS-a9P_fH2v_tN6GlM1f3sMOlqPqbfOB7S9dp2_1_Bxy2Br33pr6l94g3HTLB1zDWvJ6KBiZQD2B5ofBp4
sourcetypeAggregation Database
isCDItrue
recordtypearticle
pqid1773043381
display
typearticle
titleEndometrial cancer
sourceAlma/SFX Local Collection
creatorMorice, Philippe, Dr Prof ; Leary, Alexandra, MD ; Creutzberg, Carien, Prof ; Abu-Rustum, Nadeem, Prof ; Darai, Emile, Prof
creatorcontribMorice, Philippe, Dr Prof ; Leary, Alexandra, MD ; Creutzberg, Carien, Prof ; Abu-Rustum, Nadeem, Prof ; Darai, Emile, Prof
descriptionSummary Endometrial cancer is the most common gynaecological tumour in developed countries, and its incidence is increasing. The most frequently occurring histological subtype is endometrioid adenocarcinoma. Patients are often diagnosed when the disease is still confined to the uterus. Standard treatment consists of primary hysterectomy and bilateral salpingo-oophorectomy, often using minimally invasive approaches (laparoscopic or robotic). Lymph node surgical strategy is contingent on histological factors (subtype, tumour grade, involvement of lymphovascular space), disease stage (including myometrial invasion), patients' characteristics (age and comorbidities), and national and international guidelines. Adjuvant treatment is tailored according to histology and stage. Various classifications are used to assess the risks of recurrence and to determine optimum postoperative management. 5 year overall survival ranges from 74% to 91% in patients without metastatic disease. Trials are ongoing in patients at high risk of recurrence (including chemotherapy, chemoradiation therapy, and molecular targeted therapies) to assess the modalities that best balance optimisation of survival with the lowest adverse effects on quality of life.
identifier
0ISSN: 0140-6736
1EISSN: 1474-547X
2DOI: 10.1016/S0140-6736(15)00130-0
3PMID: 26354523
4CODEN: LANCAO
languageeng
publisherEngland: Elsevier Ltd
subjectAbridged Index Medicus ; Adult ; Aged ; Antineoplastic Agents - therapeutic use ; Cancer ; Chemotherapy ; Combined Modality Therapy ; Comorbidity ; Early Detection of Cancer ; Endometrial cancer ; Endometrial Neoplasms - epidemiology ; Endometrial Neoplasms - pathology ; Endometrial Neoplasms - therapy ; Female ; Genetic Counseling - methods ; Humans ; Hysterectomy ; Internal Medicine ; Lymph Node Excision - methods ; Metastasis ; Middle Aged ; Molecular Targeted Therapy - methods ; Mutation ; Mutation - genetics ; Neoadjuvant Therapy ; Neoplasm Invasiveness ; Neoplasm Metastasis ; Neoplasm Recurrence, Local - therapy ; Neoplasm Staging ; Preoperative Care - methods ; Prognosis ; Risk Factors ; Survival Analysis ; Tumors ; Uterine Hemorrhage - etiology ; Womens health
ispartofThe Lancet (British edition), 2015, Vol.387 (10023), p.1094-1108
rights
0Elsevier Ltd
12016 Elsevier Ltd
2Copyright © 2016 Elsevier Ltd. All rights reserved.
3COPYRIGHT 2016 Elsevier B.V.
4Copyright Elsevier Limited Mar 12, 2016
lds50peer_reviewed
citedbyFETCH-LOGICAL-c693t-2e2084113976b281e1882dff0e6fd77d2e854f5767756015b29dd4c434404eaf3
citesFETCH-LOGICAL-c693t-2e2084113976b281e1882dff0e6fd77d2e854f5767756015b29dd4c434404eaf3
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26354523$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Morice, Philippe, Dr Prof
1Leary, Alexandra, MD
2Creutzberg, Carien, Prof
3Abu-Rustum, Nadeem, Prof
4Darai, Emile, Prof
title
0Endometrial cancer
1The Lancet (British edition)
addtitleLancet
descriptionSummary Endometrial cancer is the most common gynaecological tumour in developed countries, and its incidence is increasing. The most frequently occurring histological subtype is endometrioid adenocarcinoma. Patients are often diagnosed when the disease is still confined to the uterus. Standard treatment consists of primary hysterectomy and bilateral salpingo-oophorectomy, often using minimally invasive approaches (laparoscopic or robotic). Lymph node surgical strategy is contingent on histological factors (subtype, tumour grade, involvement of lymphovascular space), disease stage (including myometrial invasion), patients' characteristics (age and comorbidities), and national and international guidelines. Adjuvant treatment is tailored according to histology and stage. Various classifications are used to assess the risks of recurrence and to determine optimum postoperative management. 5 year overall survival ranges from 74% to 91% in patients without metastatic disease. Trials are ongoing in patients at high risk of recurrence (including chemotherapy, chemoradiation therapy, and molecular targeted therapies) to assess the modalities that best balance optimisation of survival with the lowest adverse effects on quality of life.
subject
0Abridged Index Medicus
1Adult
2Aged
3Antineoplastic Agents - therapeutic use
4Cancer
5Chemotherapy
6Combined Modality Therapy
7Comorbidity
8Early Detection of Cancer
9Endometrial cancer
10Endometrial Neoplasms - epidemiology
11Endometrial Neoplasms - pathology
12Endometrial Neoplasms - therapy
13Female
14Genetic Counseling - methods
15Humans
16Hysterectomy
17Internal Medicine
18Lymph Node Excision - methods
19Metastasis
20Middle Aged
21Molecular Targeted Therapy - methods
22Mutation
23Mutation - genetics
24Neoadjuvant Therapy
25Neoplasm Invasiveness
26Neoplasm Metastasis
27Neoplasm Recurrence, Local - therapy
28Neoplasm Staging
29Preoperative Care - methods
30Prognosis
31Risk Factors
32Survival Analysis
33Tumors
34Uterine Hemorrhage - etiology
35Womens health
issn
00140-6736
11474-547X
fulltexttrue
rsrctypearticle
creationdate2015
recordtypearticle
recordideNqNkl1rFDEUhoNY7Fq98V4RvKng1JPJ1wyCUkptCwUvVPAuZJMza-p8bJMZof_ezK52p8tiSyCB8Jwnb-Al5CWFIwpUvv8KlEMmFZOHVLwFoAwyeERmlCueCa5-PCazW2SfPI3xCgC4BPGE7OeSCS5yNiMvTlvXNdgHb-rX1rQWwzOyV5k64vO_5wH5_vn028l5dvnl7OLk-DKzsmR9lmMOBaeUlUrO84IiLYrcVRWgrJxSLsdC8EooqZSQQMU8L53jljPOgaOp2AE5XHuXobseMPa68dFiXZsWuyFqqpTiJVAlE_pmC73qhtCmdCPFgDNW0A21MDVq31ZdH4wdpfpY0FIyDoL_l-KSgUiRWaKOdlBpOWy87VqsfLq_o33QwPSFVzsG9NS4E5ga3k2A-RB9izFt0S9-9nFhhhjvJnwAPrWLNW5DF2PASi-Db0y40RT0WEG9qqAe-6Wp0KsKatjEXg7zBt3t1L_OJeDDltj63vS-a9P_fH2v_tN6GlM1f3sMOlqPqbfOB7S9dp2_1_Bxy2Br33pr6l94g3HTLB1zDWvJ6KBiZQD2B5ofBp4
startdate2015
enddate2015
creator
0Morice, Philippe, Dr Prof
1Leary, Alexandra, MD
2Creutzberg, Carien, Prof
3Abu-Rustum, Nadeem, Prof
4Darai, Emile, Prof
general
0Elsevier Ltd
1Elsevier B.V
2Elsevier Limited
scope
0CGR
1CUY
2CVF
3ECM
4EIF
5NPM
6AAYXX
7CITATION
8BKMMT
9BSHEE
100TT
110TZ
120U~
133V.
147QL
157QP
167RV
177TK
187U7
197U9
207X7
217XB
2288A
2388C
2488E
2588G
2688I
278AF
288AO
298C1
308C2
318FE
328FH
338FI
348FJ
358FK
368G5
37ABUWG
38AN0
39ASE
40AZQEC
41BBNVY
42BEC
43BENPR
44BHPHI
45C1K
46DWQXO
47FPQ
48FYUFA
49GHDGH
50GNUQQ
51GUQSH
52H94
53HCIFZ
54K6X
55K9-
56K9.
57KB0
58KB~
59LK8
60M0R
61M0S
62M0T
63M1P
64M2M
65M2O
66M2P
67M7N
68M7P
69MBDVC
70NAPCQ
71PQEST
72PQQKQ
73PQUKI
74Q9U
75S0X
767X8
sort
creationdate2015
titleEndometrial cancer
authorMorice, Philippe, Dr Prof ; Leary, Alexandra, MD ; Creutzberg, Carien, Prof ; Abu-Rustum, Nadeem, Prof ; Darai, Emile, Prof
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-c693t-2e2084113976b281e1882dff0e6fd77d2e854f5767756015b29dd4c434404eaf3
rsrctypearticles
prefilterarticles
languageeng
creationdate2015
topic
0Abridged Index Medicus
1Adult
2Aged
3Antineoplastic Agents - therapeutic use
4Cancer
5Chemotherapy
6Combined Modality Therapy
7Comorbidity
8Early Detection of Cancer
9Endometrial cancer
10Endometrial Neoplasms - epidemiology
11Endometrial Neoplasms - pathology
12Endometrial Neoplasms - therapy
13Female
14Genetic Counseling - methods
15Humans
16Hysterectomy
17Internal Medicine
18Lymph Node Excision - methods
19Metastasis
20Middle Aged
21Molecular Targeted Therapy - methods
22Mutation
23Mutation - genetics
24Neoadjuvant Therapy
25Neoplasm Invasiveness
26Neoplasm Metastasis
27Neoplasm Recurrence, Local - therapy
28Neoplasm Staging
29Preoperative Care - methods
30Prognosis
31Risk Factors
32Survival Analysis
33Tumors
34Uterine Hemorrhage - etiology
35Womens health
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Morice, Philippe, Dr Prof
1Leary, Alexandra, MD
2Creutzberg, Carien, Prof
3Abu-Rustum, Nadeem, Prof
4Darai, Emile, Prof
collection
0Medline
1MEDLINE
2MEDLINE (Ovid)
3MEDLINE
4MEDLINE
5PubMed
6CrossRef
7Gale General OneFile (A&I only)
8Academic OneFile (A&I only)
9News PRO
10Pharma and Biotech Premium PRO
11Global News & ABI/Inform Professional
12ProQuest Central (Corporate)
13Bacteriology Abstracts (Microbiology B)
14Calcium & Calcified Tissue Abstracts
15Nursing & Allied Health Database
16Neurosciences Abstracts
17Toxicology Abstracts
18Virology and AIDS Abstracts
19Health & Medical Collection
20ProQuest Central (purchase pre-March 2016)
21Biology Database (Alumni Edition)
22Healthcare Administration Database (Alumni)
23Medical Database (Alumni Edition)
24Psychology Database (Alumni)
25Science Database (Alumni Edition)
26STEM Database
27ProQuest Pharma Collection
28Public Health Database
29Lancet Titles
30ProQuest SciTech Collection
31ProQuest Natural Science Collection
32Hospital Premium Collection
33Hospital Premium Collection (Alumni Edition)
34ProQuest Central (Alumni) (purchase pre-March 2016)
35Research Library (Alumni Edition)
36ProQuest Central (Alumni Edition)
37British Nursing Database
38British Nursing Index
39ProQuest Central Essentials
40Biological Science Collection
41eLibrary
42ProQuest Central
43Natural Science Collection
44Environmental Sciences and Pollution Management
45ProQuest Central Korea
46British Nursing Index (BNI) (1985 to Present)
47Health Research Premium Collection
48Health Research Premium Collection (Alumni)
49ProQuest Central Student
50Research Library Prep
51AIDS and Cancer Research Abstracts
52SciTech Premium Collection
53British Nursing Index
54Consumer Health Database (Alumni Edition)
55ProQuest Health & Medical Complete (Alumni)
56Nursing & Allied Health Database (Alumni Edition)
57ProQuest Newsstand Professional
58ProQuest Biological Science Collection
59Consumer Health Database
60Health & Medical Collection (Alumni Edition)
61Healthcare Administration Database
62Medical Database
63Psychology Database
64Research Library
65Science Database
66Algology Mycology and Protozoology Abstracts (Microbiology C)
67Biological Science Database
68Research Library (Corporate)
69Nursing & Allied Health Premium
70ProQuest One Academic Eastern Edition
71ProQuest One Academic
72ProQuest One Academic UKI Edition
73ProQuest Central Basic
74SIRS Editorial
75MEDLINE - Academic
jtitleThe Lancet (British edition)
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Morice, Philippe, Dr Prof
1Leary, Alexandra, MD
2Creutzberg, Carien, Prof
3Abu-Rustum, Nadeem, Prof
4Darai, Emile, Prof
formatjournal
genrearticle
ristypeJOUR
atitleEndometrial cancer
jtitleThe Lancet (British edition)
addtitleLancet
date2015
risdate2015
volume387
issue10023
spage1094
epage1108
pages1094-1108
issn0140-6736
eissn1474-547X
codenLANCAO
abstractSummary Endometrial cancer is the most common gynaecological tumour in developed countries, and its incidence is increasing. The most frequently occurring histological subtype is endometrioid adenocarcinoma. Patients are often diagnosed when the disease is still confined to the uterus. Standard treatment consists of primary hysterectomy and bilateral salpingo-oophorectomy, often using minimally invasive approaches (laparoscopic or robotic). Lymph node surgical strategy is contingent on histological factors (subtype, tumour grade, involvement of lymphovascular space), disease stage (including myometrial invasion), patients' characteristics (age and comorbidities), and national and international guidelines. Adjuvant treatment is tailored according to histology and stage. Various classifications are used to assess the risks of recurrence and to determine optimum postoperative management. 5 year overall survival ranges from 74% to 91% in patients without metastatic disease. Trials are ongoing in patients at high risk of recurrence (including chemotherapy, chemoradiation therapy, and molecular targeted therapies) to assess the modalities that best balance optimisation of survival with the lowest adverse effects on quality of life.
copEngland
pubElsevier Ltd
pmid26354523
doi10.1016/S0140-6736(15)00130-0